Gene Therapy Prospects Make Axovant Sciences A Compelling Buy For 2018 [Seeking Alpha]
Axon Enterprise, Inc. (AXON)
Last axon enterprise, inc. earnings: 2/7 04:15 pm
Check Earnings Report
US:NYSE Investor Relations:
investors.axovant.com/investors/sec-filings
Company Research
Source: Seeking Alpha
Summary Axovant Sciences' ( AXON ) licensing deal with Oxford BioMedica ( OTCPK:OXBDF ) is nothing short of a masterstroke. This deal has opened up the gene therapy segment for Axovant Sciences and has positioned the company to make a solid entry in the neurodegenerative disease segment. This transformation from being a small molecule player to a very potent lentiviral vector gene therapy company initially targeting Parkinson's disease or PD has been well received by the investor community. The stock has jumped by a whopping 284% since start of June 2018. But all is not lost yet. Even now, I strongly believe that all those who have missed on the initial rally should be picking up Axovant Sciences since there are solid science and robust commercial fundamentals backing this deal. In this article, I will explain why I consider Axovant Sciences to be a promising investment opportunity for 2018. Parkinson's Disease Is An Area With High Unmet Demand This lic
Show less
Read more
Impact Snapshot
Event Time:
AXON
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AXON alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AXON alerts
High impacting Axon Enterprise, Inc. news events
Weekly update
A roundup of the hottest topics
AXON
News
- Why Is Axon (AXON) Up 2.1% Since Last Earnings Report? [Yahoo! Finance]Yahoo! Finance
- Global Swarm Intelligence Market Analysis Report 2024: Ant Colony Optimization Leads Market with 45.0% Share in 2023 - Forecast to 2030 for the $300+ Million Industry [Yahoo! Finance]Yahoo! Finance
- 25 US States with the Highest Number of Police Officers Per Capita [Yahoo! Finance]Yahoo! Finance
- Beyond The TASER: How Axon Is Revolutionizing Public Safety (And Your Portfolio) [Seeking Alpha]Seeking Alpha
- 20 Largest Police Departments in the US [Yahoo! Finance]Yahoo! Finance
AXON
Earnings
- 2/27/24 - Beat
AXON
Sec Filings
- 3/18/24 - Form PRE
- 3/18/24 - Form 4
- 3/18/24 - Form 4
- AXON's page on the SEC website